Sunday, June 30, 2019

PETO'S PARADOX: Why are there whales?


Linda and Amanda
30 or so years ago
That little tyke now is the mother of two of my great grand children
My, how time does fly when you're having fun!

Peto’s Paradox In a nutshell:  What causes a cancer?  Well, fundamentally, a cancer arises when a cell divides incorrectly, affecting the functionality of “oncogenes” and “tumor-suppressor genes”.  It follows, does it not, that the more cells you have, the more likely you are to develop a tumor?  Thus, elephants ought to be much more likely to die of cancer than humans, and truly colossal whales should be almost impossible to exist.  But there are elephants, and there are whales – and neither is nearly as susceptible to cancer as you and I.  Why?

Well, maybe it’s environment.  We know now that environment somehow influence life and heredity by  festooning the DNA molecule with “markers” that determine which genes are expressed – translated into proteins.  Whales live in salt water and eat fish: maybe that helps reduce the probability of a pernicious mutation occurring.  However, elephants live on land, roll in mud, and eat grass – and they are similarly protected.  So it isn’t environment.  Perhaps if we rolled in mud several times each day, washing it off with salt water, and lived on raw fish washed down with liquid extract of kale, we would have less cancer.  Somehow, I doubt it.

The research described in this article canters on the well-known tumor-suppressor gene TP53.  TP53 codes for a protein called p53 which tells a “broken” cell not to duplicate its DNA and reproduce.  In effect, it serves as a cellular grim reaper.  Whales and elephants have TP53 genes very much like our own – but somehow much more effective.  Or maybe they simply have more of them.  Whatever.  Research is ongoing.  Stay tuned.


I have written about this before:



Thursday, June 27, 2019

OVCA BASICS


Linda bestrides the World

If you have been reading this blog right along most of this already will be familiar to you.  If not, here is an easy way to begin to catch up.

Saturday, June 22, 2019

BEST CANCER CENTERS


Hurricane Ridge, 1984

Most of these blogs are about things I hope you never really need to know.  That goes for this one, too, in spades.

Below, NCI provides you with a list of top cancer centers.  For Washington, for instance, there’s Fred Hutch, and for Oregon there is the Knight Cancer Center, in Portland.  If you live in the Eastern Seaboard you can commute to a nearby center by subway or scooter, but if you live in North Dakota, Wyoming or, especially, Alaska you are SOL; an airplane would be required.

If you do get a cancer diagnosis, it is vital that you get the best care available.  These 70 NCI cancer centers are the best.  Tuck this bit of info away somewhere; in your file called “Important stuff I hope I never need.”

Wednesday, June 19, 2019

TWO THINGS:




VIDEO: 2-year-old who fought rare ovarian cancer is now cancer-free
                   
                                          Kerri


Do you need proof that the Devil is real and is out to get us?  Well, read this article about a beautiful two-year-old stricken with a rare form of ovarian cancer.  Do you require evidence that sometimes God, or maybe medical science, or possibly both, can frustrate the Devil’s most nasty tricks.  Then read the same article.  It appears that our Unfriendly Companion got his ass kicked – at least for now.  Way to go. Kerri!


A few days ago I suggested that you remember the drug name Olaparib, which has proven to be an effective “maintenance” drug.  This means that Olaparib will, often, significantly prolong remission after initial therapy.  Well, drug giant AstroZeneca has obtained approval for a drug, called Lynparza, which does the same thing.


But, oh heck!  Further research indicates that Lynparza is just another name for Olaparib.  So now you have two names to remember.  I wrote about Olaparib a few weeks ago.  Right now I feel a little stupid.


Sunday, June 16, 2019

EAT YOUR GREENS, DAMMIT?


TWO QUEENS

So I ask myself: “Which three vegetables do you least like to eat?”  The answer readily pops out: “broccoli, Brussels sprouts, and cauliflower!”  Turns out that these three malignant vegetables, and others that I also don’t like, contain a substance – indole 3 carbinol, or I3C - that is an active agent against cancer.  Why couldn’t the good stuff have been in strawberries, peaches, and chocolate?

This somewhat unwelcome bit of news is derived from important research recently published, supported by the NCI.  To summarize and oversimplify:

You all have known for years that there are two kinds of genes (actually, proteins they code for) that are implicated in most cancers.  These are tumor-suppressor genes and oncogenes.  When out of whack due to mutation, either of these can be responsible for tumor growth.

 Most cancer therapies have been aimed at oncogenes.  MYC, for instance, is a gene that is necessary for cell growth.  When mutated, it can cause uncontrolled growth – i.e., a tumor.  But, because MYC plays a vital role in normal cellular activity, it is tricky to fiddle with.

Well, some smart folks in Boston have approached the problem in an entirely new way.  Instead of trying to discourage the oncogenes, they have elected to encourage the tumor suppressors.
To comprehend what they are doing you really ought to read the link at the bottom of the page.  But because I know you won’t, here is a clumsy summary:

Something called PTEN (apparently a “signaling sequence”), an important tumor suppressor, somehow is “silenced” in certain cancers.  The culprit, it turns out, is something called WWP1 – which just happens to be “regulated” by the aforesaid MYC.  And guess what they found that helped stifle WWP1?  Why, I3C, of course.  They are looking for something more potent, but so far, no luck.  Clinical trials loom just over the horizon.  Many mice already are dying. 

So, eat your greens, dammit!  It is possible to buy I3C over-the-counter as a health supplement, but I am not rushing out to buy some.




Thursday, June 13, 2019

SENESCENCE: A NEW WORD, A NEW TOOL


Not a senescent cell in her cute little body

Folks in Montreal have just published a paper that has stirred up a lot of interest.  They are suggesting a “one-two” punch therapy to combat ovarian cancer.  Briefly, they hit it with, I think, standard chemo together with a PARP inhibitor, and then follow up with something I had never heard of – an anti-senescence drug.  Preliminary results are so good that they got their paper into a Nature journal, which can be difficult.  Note that they are still in the cell-line stage; they haven’t even progressed to lab rats, let alone humans.  Under the best of circumstances it will be a long time until their drugs show up on Rite Aid shelves!

Did you know that there are such things as anti-senescence drugs?  I sure didn’t.  It appears that some cells, when they become old and useless, live on causing trouble (including cancer) instead of obeying the order of apoptosis and croaking.  Apparently anti-senescence drugs have been studied, at least partly to combat aging.  If I read these press releases correctly, the effect of chemo in cancer is to kill cancer cells, yes, but it also puts some into a state of senescence.  Then they administer a regimen of anti-senescence drugs, possibly killing off all the remaining bad cells.

I hope this works.  It might even be a real cure.  I hope so.

Tuesday, June 11, 2019

STEM CELLS AND SNAKE OIL

\
Do we have too much regulation, too much gullibility, or too much desperation?  The answer, probably, is – yes.  The article cited below describes an instance wherein the court system put the (temporary) kibosh on a “clinic” that specializes in extracting fat from your butt, extracting stem cells therefrom, multiplying and “purifying” them, then injecting them into some sick organ or joint – and, like magic – a cure results!   Oh yeah?  Is there any evidence that this sort of thing actually works?  No.  There have been no legitimate clinical trials, as far as I know – although there is a smattering of positive anecdotal evidence.  The FDA seems to be flummoxed.  There are hundreds of these stem-cell outfits, promising to cure every disease from Acne to Zika.  I have railed against adds for these scams on Facebook multiple times.  It may be that someday something miraculous will come of all this.  In the meantime: CAVEAT EMPTOR!

Saturday, June 8, 2019

HOW TO USE THIS BLOG: A tutorial


At least they don't have to shave every day!

It occurs to me that this may be getting out-of-hand.  So far I have written 687 blogs, all but a tiny minority devoted to the fight against ovarian cancer. That number is so huge that even I cannot remember what I have covered, and when.  As the professed purpose of all this work is to keep you up to snuff – to know what to ask your oncologist if ever – God forbid! – you need one, I want to remind you that you can search the whole mess for terms pertaining to your needs or curiosities.
Just go to Google and type in Myrl’sBlog.  This should allow you to access the entire collection.  In the upper left corner (on my machine, at least) there will appear a “Search” line.  Use it.  I tried “clinical trials”, and got 20 hits.  Early detection yielded 14 articles, and “Review” dredged up 10.  Even the humble word “Damn” found seven hits.
By the way, if you are frightened that Google is swallowing the world, Yahoo’s search engine seems to work just as well.,

Thursday, June 6, 2019

OLAPARIB: Remember the name


Linda & family, Kalamazoo

Remember this name:  Olaparib.  Olaparib is a PARP inhibitor, one of several immunotherapy approaches to cancer therapy.  Lately it has been shown to be effective against ovarian cancer, both the kind involved with BRCA mutation, and wild-type BRCA occurrences.

 “Wild-type” in the curious language of medicine, most often merely means “normal”.  It arose from initial study of fruit flies: they would put a chunk of rotten fruit on the window-sill, then capture the inevitable fruit flies and put them in a bottle.  They were looking for mutants, recognized by having red eyes.  The rest were just “wild type”

Can you imagine a career spent looking at fruit flies under a microscope?  I’d almost rather be a dentist.

And, in the first paragraph, where I used the word effective, I really meant “effective”.  Olaparib prolongs remission in some cases, but in its present state is not a cure.


Olaparib is a product of AstroZenica, a Swedish-UK amalgam headquartered in Britain.  Its shares currently sell for about $39.  Do not regard that as investment advice.

Wednesday, June 5, 2019

A DIGRESSION: Autism


Our skinny period
Probably early 80s
Cat is Whiskers

The latest Economist has a very interesting medical article that – while it doesn’t have an obvious connection to ovarian cancer – I would like to pass on to you.


Autism is often in the news, so you know what it is.  Now doctors talk about “ASD”, which stands for autism spectral disorder.  Asperger’s syndrome is on the ASD spectrum.  One in 59 newborns currently express some form of ASD.

Well, it turns out that ASD likely results from an abnormality in gut bacteria, and may respond to something called MTT (microbiota transfer therapy), involving – among other things – that favorite of 11-year-old boys, fecal transplants.  (See ancient blog https://ljb-quiltcutie.blogspot.com/2012/11/microbes-maketh-man.html  for context.)

 It appears that certain gut bacteria are necessary to the proper functioning of several neuro-transmitters that play a vital role in the brain.  Detailed and convincing cause-and-effect is absent, but it is robustly demonstrated that people with ASD consistently lack  specific bacterial species common to the human to the alimentary tract. 

This (recognition of the vital role of gut bacteria in human health) is described by some as a “paradigm shift” (think: plate tectonics or the atomic theory).  The research described by the Economist has been fast-tracked by the FDA, and is being avidly pursued by an outfit called Fox Therapeutic Group, located in Massachusetts.  If Fox were on the stock exchange and I had any money I would buy some of their stock.  But they aren’t. and I don’t.


Saturday, June 1, 2019

CANCER STATISTICS: Ugly


The Kelly girls, behaving badly
But they all have grown into young women of whom I am very proud

If you are in a euphoric mood and feel the need to regress back to reality, you can do worse than to glance at cancer statistic from NIH Surveillance, Epidemiology and End Results, brought to you anew in easily accessed graphical form:


Particularly discouraging, to me, was the minuscule progress we have made against ovarian cancer since 1992.  The five-year survival rate of OVCA victims remains below 50%.  Miserable, disgraceful, and sad.